Nucleic acid aptamers in human viral disease

Archivum Immunologiae et Therapiae Experimentalis

Volumn 52, Issue 5, 2004, Pages 307-315

  Zhang, Zhiren ^a   Blank, Michael ^b   Schluesener, Hermann J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NascaCell Technologies AG   (Germany)

Author keywords

Analytic applications; Aptamer; HCV; HIV; Human viral diseases; SELEX; Therapeutic applications

Indexed keywords

APTAMER; NUCLEIC ACID; OLIGONUCLEOTIDE;

ANALYTIC METHOD; HUMAN IMMUNODEFICIENCY VIRUS; LIGAND BINDING; NONHUMAN; PROTEIN STABILITY; PROTEIN TARGETING; REVIEW; SEQUENCE ANALYSIS; VIRUS INFECTION; VIRUS ISOLATION;

HEPATITIS C; HIV INFECTIONS; HUMANS; KIDNEY; OLIGONUCLEOTIDES; VIRUS DISEASES;

EID: 10344264474     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Allen P., Collins B., Brown D., Hostomsky Z. and Gold L. (1996): A specific RNA structural motif mediates high affinity binding by the HIV-1 nucleocapsid protein (NCp7). Virology, 225, 306-315.
2. Andreola M. L., Calmels C., Michel J., Toulme J. J. and Litvak S. (2000): Towards the selection of phosphorothioate aptamers optimizing in vitro selection steps with phosphorothioate nucleotides. Eur. J. Biochem., 267, 5032-5040.
3. Berglund J. A., Charpentier B. and Rosbash M. (1997): A high affinity binding site for the HIV-1 nucleocapsid protein. Nucleic Acids Res., 25, 1042-1049.
4. Biroccio A., Hamm J., Incitti I., De Francesco R. and Tomei L. (2002): Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol., 76, 3688-3696.
5. Bishop J. S., Guy-Caffey J. K., Ojwang J. O., Smith S. R., Hogan M. E., Cossum P. A., Rando R. F. and Chaudhary N. (1996): Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J. Biol. Chem., 271, 5698-5703.
6. Blank M., Weinschenk T., Priemer M. and Schluesener H. (2001): Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels: selective targeting of endothelial regulatory protein pigpen. J. Biol. Chem., 276, 16464-16468.
7. Bless N. M., Smith D., Charlton J., Czermak B. J., Schmal H., Friedl H. P. and Ward P. A. (1997): Protective effects of an aptamer inhibitor of neutrophil elastase in lung inflammatory injury. Curr. Biol., 7, 877-880.
8. Boiziau C., Dausse E., Yurchenko L. and Toulme J. J. (1999): DNA aptamers selected against the HIV-1 trans-activation-responsive RNA element form RNA-DNA kissing complexes. J. Biol. Chem., 274, 12730-12737.
9. Bridonneau P., Chang Y. F., O'Connell D., Gill S. C., Snyder D. W., Johnson L., Goodson T. Jr., Herron D. K. and Parma D. H. (1998): High-affinity aptamers selectively inhibit human nonpancreatic secretory phospholipase A2 (hnps-PLA2). J. Med. Chem., 41, 778-786.
10. Brody E. N. and Gold L. (2000): Aptamers as therapeutic and diagnostic agents. J. Biotechnol., 74, 5-13.
11. Buckheit R. W. Jr., Roberson J. L., Lackman-Smith C., Wyatt J. R., Vickers T. A. and Ecker D. J. (1994): Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum. Retroviruses, 10, 1497-1506.
12. Burke D. H. and Gold L. (1997): RNA aptamers to the adenosine moiety of S-adenosyl methionine: structural inferences from variations on a theme and the reproducibility of SELEX. Nucleic Acids Res., 25, 2020-2024.
13. Carrasquillo K. G., Ricker J. A., Rigas I. K., Miller J. W., Gragoudas E. S. and Adamis A. P. (2003): Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest. Ophthalmol. Vis. Sci., 44, 290-299.
14. Chaloin L., Lehmann M. J., Sczakiel G. and Restle T. (2002): Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res., 30, 4001-4008.
15. Charlton J., Sennello J. and Smith D. (1997): In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem. Biol., 4, 809-816.
16. Cherepanov P., Este J. A., Rando R. F., Ojwang J. O., Reekmans G., Steinfeld R., David G., De Clercq E. and Debyser Z. (1997): Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Mol. Pharmacol., 52, 771-780.
17. Dang C. and Jayasena S. D. (1996): Oligonucleotide inhibitors of Taq DNA polymerase facilitate detection of low copy number targets by PCR. J. Mol. Biol., 264, 268-278.
18. Darfeuille F., Arzumanov A., Gait M. J., Di Primo C. and Toulme J. J. (2002): 2'-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry, 41, 12186-12192.
19. Darfeuille F., Arzumanov A., Gryaznov S., Gait M. J., Di Primo C. and Toulme J. J. (2002): Loop-loop interaction of HIV-1 TAR RNA with N3'→P5' deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc. Natl. Acad. Sci. USA, 99, 9709-9714.
20. Davis K. A., Lin Y., Abrams B. and Jayasena S. D. (1998): Staining of cell surface human CD4 with 2'-F-pyrimidine-containing RNA aptamers for flow cytometry. Nucleic Acids Res., 26, 915-924.
21. DeAnda A. Jr., Coutre S. E., Moon M. R., Vial C. M., Griffin L. C., Law V. S., Komeda M., Leung L. L. and Miller D. C. (1994): Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann. Thorac. Surg., 58, 344-350.
22. de Soultrait V. R., Lozach P. Y., Altmeyer R., Tarrago-Litvak L., Litvak S. and Andreola M. L. (2002): DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J. Mol. Biol., 324, 195-203.
23. Dewey T. M., Mundt A. A., Crouch G. J., Zyzniewski M. C. and Eaton B. E. (1995): New uridine derivatives for systematic evolution of RNA ligands by exponential enrichment. J. Am. Chem. Soc., 117, 8474-8475.
24. Dougan H., Lyster D. M., Vo C. V., Stafford A., Weitz J. I. and Hobbs J. B. (2000): Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl. Med. Biol., 27, 289-297.
25. Eaton B. E. (1997): The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets. Curr. Opin. Chem. Biol., 1, 10-16.
26. El Dirani-Diab R., Sarih-Cottin L., Delord B., Dumon B., Moreau S., Toulme J. J., Fleury H. and Litvak S. (1997): Phosphorothioate oligonucleotides derived from human immunodeficiency virus type 1 (HIV-1) primer tRNALys3 are strong inhibitors of HIV-1 reverse transcriptase and arrest viral replication in infected cells. Antimicrob. Agents Chemother., 41, 2141-2148.
27. Ellington A. D. and Szostak J. W. (1990): In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818-822.
28. Ellington A. D. and Szostak J. W. (1992): Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. Nature, 355, 850-852.
29. Eyetech Study Group (2002): Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina, 22, 143-152.
30. Eyetech Study Group (2003): Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology, 110, 979-986.
31. Floege J., Ostendorf T., Janssen U., Burg M., Radeke H. H., Vargeese C., Gill S. C., Green L. S. and Janjic N. (1999): Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol., 154, 169-179.
32. Fukuda K., Vishnuvardhan D., Sekiya S., Hwang J., Kakiuchi N., Taira K., Shimotohno K., Kumar P. K. and Nishikawa S. (2000): Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. Eur. J. Biochem., 267, 3685-3694.
33. Gold L., Polisky B., Uhlenbeck O. and Yarus M. (1995): Diversity of oligonucleotide functions. Annu. Rev. Biochem., 64, 763-797.
34. Griffin L. C., Tidmarsh G. F., Bock L. C., Toole J. J. and Leung L. L. (1993): In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood, 81, 3271-3276.
35. Harada K. and Frankel A. D. (1995): Identification of two novel arginine binding DNAs. EMBO J., 14, 5798-5811.
36. Hess G. P., Ulrich H., Breitinger H. G., Niu L., Gameiro A. M., Grewer C., Srivastava S., Ippolito J. E., Lee S. M., Jayaraman V. and Coombs S. E. (2000): Mechanism-based discovery of ligands that counteract inhibition of the nicotinic acetylcholine receptor by cocaine and MK-801. Proc. Natl. Acad. Sci. USA, 97, 13895-13900.
37. Hicke B. J. and Stephens A. W. (2000): Escort aptamers: a delivery service for diagnosis and therapy. J. Clin. Invest., 106, 923-928.
38. Homann M. and Goringer H. U. (1999): Combinatorial selection of high affinity RNA ligands to live African trypanosomes. Nucleic Acids Res., 27, 2006-2014.
39. Hwang J., Fauzi H., Fukuda K., Sekiya S., Kakiuchi N., Shimotohno K., Taira K., Kusakabe I. and Nishikawa S. (2000): The RNA aptamer-binding site of hepatitis C virus NS3 protease. Biochem. Biophys. Res. Commun., 279, 557-562.
40. Jayasena S. D. (1999): Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem., 45, 1628-1650.
41. Jenison R. D., Gill S. C., Pardi A. and Polisky B. (1994): High-resolution molecular discrimination by RNA. Science, 263, 425-429.
42. Jenison R. D., Jennings S. D., Walker D. W., Bargatze R. F. and Parma D. (1998): Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev., 8, 265-279.
43. Jhaveri S., Olwin B. and Ellington A. D. (1998): In vitro selection of phosphorothiolated aptamers. Bioorg. Med. Chem. Lett., 8, 2285-2290.
44. Jiang F., Gorin A., Hu W., Majumdar A., Baskerville S., Xu W., Ellington A. and Patel D. J. (1999): Anchoring an extended HTLV-1 Rex peptide within a RNA major groove containing junctional base triples. Structure Fold Des., 7, 1461-1472.
45. Kenan D. J. and Keene J. D. (1999): In vitro selection of aptamers from RNA libraries. Methods Mol. Biol., 118, 217-231.
46. Khati M., Schuman M., Ibrahim J., Sattentau Q., Gordon S. and James W. (2003): Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers. J. Virol., 77, 12692-12698.
47. Kikuchi K., Umehara T., Fukuda K., Hwang J., Kuno A., Hasegawa T. and Nishikawa S. (2003): Structure-inhibition analysis of RNA aptamers that bind to HCV IRES. Nucleic Acids Res. Suppl., 3, 291-292.
48. Kim S., Shi H., Lee D. K. and Lis J. T. (2003): Specific SR protein-dependent splicing substrates identified through genomic SELEX. Nucleic Acids Res., 31, 1955-1961.
49. King D. J., Ventura D. A., Brasier A. R. and Gorenstein D. G. (1998): Novel combinatorial selection of phosphorothioate oligonucleotide aptamers. Biochemistry, 37, 16489-16493.
50. Klussmann S., Nolte A., Bald R., Erdmann V. A. and Furste J. P. (1996): Mirror-image RNA that binds D-adenosine. Nat. Biotechnol., 14, 1112-1115.
51. + cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood, 94, 368-371.
52. Konopka K., Duzgunes N., Rossi J. and Lee N. S. (1998): Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs. J. Drug Target, 5, 247-259.
53. Konopka K., Lee N. S., Rossi J. and Duzgunes N. (2000): Revbinding aptamer and CMV promoter act as decoys to inhibit HIV replication. Gene, 255, 235-244.
54. Kuwasaki T., Hatta M., Takeuchi H. and Takaku H. (2003): Inhibition of human immunodeficiency virus I replication in vitro by a self-stabilized oligonucleotide with 2'-O-methyl-guanosine-uridine quadruplex motifs. J. Antimicrob. Chemother., 51, 813-819.
55. Latham J. A., Johnson R. and Toole J. J. (1994): The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2'-deoxyuridine. Nucleic Acids Res., 22, 2817-2822.
56. Lee T. C., Sullenger B. A., Gallardo H. F., Ungers G. E. and Gilboa E. (1992): Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol., 4, 66-74.
57. Marshall K. A. and Ellington A. D. (2000): In vitro selection of RNA aptamers. Methods Enzymol., 318, 193-214.
58. Martell R. E., Nevins J. R. and Sullenger B. A. (2002): Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. Mol. Ther., 6, 30-34.
59. Mazumder A., Neamati N., Ojwang J. O., Sunder S., Rando R. F. and Pommier Y. (1996): Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry, 35, 13762-13771.
60. Milligan J. F. and Uhlenbeck O. C. (1989): Determination of RNA-protein contacts using thiophosphate substitutions. Biochemistry, 28, 2849-2855.
61. Morris K. N., Jensen K. B., Julin C. M., Weil M. and Gold L. (1998): High affinity ligands from in vitro selection: complex targets. Proc. Natl. Acad. Sci. USA, 95, 2902-2907.
62. Nishikawa F., Kakiuchi N., Funaji K., Fukuda K., Sekiya S. and Nishikawa S. (2003): Inhibition of HCV NS3 protease by RNA aptamers in cells. Nucleic Acids Res., 31, 1935-1943.
63. Nolte A., Klussmann S., Bald R., Erdmann V. A. and Furste J. P. (1996): Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nat. Biotechnol., 14, 1116-1119.
64. Ojwang J. O., Buckheit R. W., Pommier Y., Mazumder A., De Vreese K., Este J. A., Reymen D., Pallansch L. A., Lackman-Smith C., Wallace T. L., Clercq E. D., Mcgrath M. S. and Rando R. F. (1995): T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 39, 2426-2435.
65. Pagratis N. C., Bell C., Chang Y. F., Jennings S., Fitzwater T., Jellinek D. and Dang C. (1997): Potent 2'-amino-, and 2'-fluoro2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat. Biotechnol., 15, 68-73.
66. Pan W., Craven R. C., Qiu Q., Wilson C. B., Wills J. W., Golovine S. and Wang J. F. (1995): Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proc. Natl. Acad. Sci. USA., 92, 11509-11513.
67. Pieken W. A., Olsen D. B., Benseler F., Aurup H. and Eckstein F. (1991): Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science, 253, 314-317.
68. Pietras K., Ostman A., Sjoquist M., Buchdunger E., Reed R. K., Heldin C. H. and Rubin K. (2001): Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res., 61, 2929-2934.
69. Rando R. F., Ojwang J., Elbaggari A., Reyes G. R., Tinder R., McGrath M. S. and Hogan M. E. (1995): Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads. J. Biol. Chem., 270, 1754-1760.
70. Ruckman J., Green L. S., Beeson J., Waugh S., Gillette W. L., Henninger D. D., Claesson-Welsh L. and Janjic N. (1998): 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem., 273, 20556-20567.
71. Joshi P. and Prasad V. R. (2002): Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J. Virol., 76, 6545-6557.
72. Sayer N., Ibrahim J., Turner K., Tahiri-Alaoui A. and James W. (2002): Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120. Biochem. Biophys. Res. Commun., 293, 924-931.
73. Singer B. S., Shtatland T., Brown D. and Gold L. (1997): Libraries for genomic SELEX. Nucleic Acids Res., 25, 781-786.
74. Smith D., Collins B. D., Heil J. and Koch T. H. (2003): Sensitivity and specificity of photoaptamer probes. Mol. Cell. Proteomics, 2, 11-18.
75. Smith R. M. and Wu G. Y. (2003): Structure-based design of hepatitis C virus inhibitors. J. Viral. Hepat., 10, 405-412.
76. Sullenger B. A., Gallardo H. F., Ungers G. E. and Gilboa E. (1990): Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell, 63, 601-608.
77. Suzuki J., Miyano-Kurosaki N., Kuwasaki T., Takeuchi H., Kawai G. and Takaku H. (2002): Inhibition of human immunodeficiency virus type 1 activity in vitro by a new self-stabilized oligonucleotide with guanosine-thymidine quadruplex motifs. J. Virol., 76, 3015-3022.
78. Tang H., Kuhen K. L. and Wong-Staal F. (1999): Lentivirus replication and regulation. Annu. Rev. Genet., 33, 133-170.
79. Tucker C. E., Chen L. S., Judkins M. B., Farmer J. A., Gill S. C. and Drolet D. W. (1999): Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J. Chromatogr. B. Biomed. Sci. Appl., 732, 203-212.
80. Tuerk C. and Gold L. (1990): Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505-510.
81. Usman N. and Blatt L. M. (2000): Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest., 106, 1197-1202.
82. Vo N. V., Oh J. W. and Lai M. M. (2003): Identification of RNA ligands that bind hepatitis C virus polymerase selectively and inhibit its RNA synthesis from the natural viral RNA templates. Virology, 307, 301-316.
83. Wallace S. T. and Schroeder R. (1998): In vitro selection and characterization of streptomycin-binding RNAs: recognition discrimination between antibiotics. RNA, 4, 112-123.
84. Wang J., Jiang H. and Liu F. (2000): In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection. RNA, 6, 571-583.
85. Watson S. R., Chang Y. F., O'Connell D., Weigand L., Ringquist S. and Parma D. H. (2000): Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo: Antisense Nucleic Acid Drug Dev., 10, 63-75.
86. Williams K. P., Liu X-H., Schumacher T. N. M., Lin H. Y., Ausiello D. A., Kim P. S. and Bartel D. P. (1997): Bioactive and nuclease-resistant L-DNA ligand of vasopressin. Proc. Natl. Acad. Sci. USA, 94, 11285-11290.
87. Willis M. C., Collins B. D., Zhang T., Green L. S., Sebesta D. P., Bell C., Kellogg E., Gill S. C., Magallanez A., Knauer S., Bendele R. A., Gill P. S., Janjic N. and Collins B. (1998): Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug. Chem., 9, 573-582.
88. Wlotzka B., Leva S., Eschgfaller B., Burmeister J., Kleinjung F., Kaduk C., Muhn P., Hess-Stumpp H. and Klussmann S. (2002): In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc. Natl. Acad. Sci. USA, 99, 8898-8902.
89. Wyatt J. R., Vickers T. A., Roberson J. L., Buckheit R. W. Jr., Klimkait T., DeBaets E., Davis P. W., Rayner B., Imbach J. L. and Ecker D. J. (1994): Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. USA, 91, 1356-1360.
90. Yamamoto R., Katahira M., Nishikawa S., Baba T., Taira K. and Kumar P. K. (2000): A novel RNA motif that binds efficiently and specifically to the Tat protein of HIV and inhibits the trans-activation by Tat of transcription in vitro and in vivo. Genes Cells, 5, 371-388.
91. Yang X., Bassett S. E., Li X., Luxon B. A., Herzog N. K., Shope R. E., Aronson J., Prow T. W., Leary J. F., Kirby R., Ellington A. D. and Gorenstein D. G. (2002): Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. Nucleic Acids Res., 30, e132.